QUILT-3.092

QUILT-3.092 is an investigational combination immunotherapy regimen being developed by ImmunityBio for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). The combination consists of CD19 t-haNK, an allogeneic, off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy engineered to target CD19, and nogapendekin alfa inbakicept (N-803, ANKTIVA), an interleukin-15 (IL-15) superagonist fusion protein. CD19 t-haNK cells are derived from the NK-92 cell line and are modified to express a CD19-targeted CAR, a high-affinity CD16 receptor (FcγRIIIa/CD16a 158V) to enhance antibody-dependent cellular cytotoxicity (ADCC), and endoplasmic reticulum-retained IL-2 (ERIL-2) for cytokine-independent growth. Nogapendekin alfa inbakicept acts to activate and expand NK cells and CD8+ T cells, synergizing with the CAR-NK therapy. The regimen is also evaluated in combination with the anti-CD20 monoclonal antibody rituximab to target both CD19 and CD20 on lymphoma cells.

Other names

CD19 t-haNK + ANKTIVACD19 t-haNK + ANKTIVA + rituximabCD19 t-haNK + N-803CD19 t-haNK + N-803 + rituximabCD19 t-haNK + nogapendekin alfa inbakiceptCD19 t-haNK + nogapendekin alfa inbakicept + rituximab